The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.
Filters
New TB
China, Hong Kong Special Administrative Region
The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.
20172021
Rifampicin test coverage among TB patients by country in 2021 (new TB)
In 2021, India had the highest value (673,008) among 193 countries.
| # | Country | Value | Change |
|---|---|---|---|
| 1 | India | 673,008 | +20.7% |
| 1 | Myanmar (2020) | 33,246 | -13.7% |
| 1 | Djibouti (2019) | 621 | -3.0% |
| 2 | China | 237,238 | -4.6% |
| 2 | Cambodia (2020) | 7,415 | – |
| 2 | Serbia (2019) | 226 | -17.8% |
Similar Datasets
Prevalence of bacteriologically-confirmed pulmonary TB who are smear positive among those aged ≥15 years, per 100,000 population
WHO (TB_ps_prev_bc_100k_sp)
The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.
WHO (TB_rdst_num_prct)
Prevalence of bacteriologically-confirmed pulmonary TB who are smear positive among those aged ≥15 years, per 100,000 population by sex.
WHO (TB_ps_prev_bc_100k_bysex_sp)
Confirmed cases of RR-/MDR-TB
WHO (TB_rr_mdr)